Cumberland Pharmaceuticals (CPIX) director granted 1,800 shares in Form 4 filing

Rhea-AI Filing Summary

Jones James reported acquisition or exercise transactions in this Form 4 filing.

Cumberland Pharmaceuticals director James Jones received a stock grant as part of his compensation. He was awarded 1,800 shares of Common Stock at a value of $2.80 per share. Following this grant, he directly owns 46,863 shares, indicating a routine, compensation-related increase in his holdings.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jones James

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,800	$2.80	$5K

Holdings After Transaction: Common Stock — 46,863 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones James

(Last) (First) (Middle)

1600 WEST END AVENUE, SUITE 1300

(Street)

NASHVILLE TENNESSEE 37203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A		1,800	A	$2.8	46,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	James Jones by /s/ John Hamm as attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cumberland Pharmaceuticals (CPIX) report for James Jones?

Cumberland Pharmaceuticals reported that director James Jones received a grant of 1,800 shares of Common Stock. The shares were awarded at a value of $2.80 per share as a compensation-related acquisition, increasing his direct ownership position in the company.

How many Cumberland Pharmaceuticals (CPIX) shares does James Jones own after this Form 4?

After the reported grant, James Jones directly owns 46,863 shares of Cumberland Pharmaceuticals Common Stock. This total reflects the addition of 1,800 granted shares and represents his post-transaction ownership as disclosed in the Form 4 filing data.

Was the James Jones transaction in Cumberland Pharmaceuticals (CPIX) a purchase or a grant?

The transaction was classified as a grant or award acquisition, not an open-market purchase. James Jones received 1,800 shares of Common Stock as compensation, coded as an “A” transaction, which indicates a grant, award, or other non-market acquisition of shares.

Does the James Jones Form 4 for Cumberland Pharmaceuticals (CPIX) involve any share sales?

The Form 4 shows no share sales by James Jones. It reports only a single acquisition transaction, reflecting a grant of 1,800 shares of Common Stock and bringing his directly owned stake to 46,863 shares with no indicated dispositions.

Is James Jones’ ownership in Cumberland Pharmaceuticals (CPIX) direct or indirect after the grant?

James Jones’ reported ownership is direct after the grant. The filing lists his nature of ownership as direct, meaning the 46,863 shares of Common Stock are held in his own name rather than through a trust, partnership, or other indirect entity.